

Lewis J Rubin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11324670/publications.pdf>

Version: 2024-02-01

254
papers

48,712
citations

3325

91
h-index

1527

218
g-index

265
all docs

265
docs citations

265
times ranked

15456
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Bosentan Therapy for Pulmonary Arterial Hypertension. <i>New England Journal of Medicine</i> , 2002, 346, 896-903. | 13.9 | 2,545 |
| 2 | A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary Hypertension. <i>New England Journal of Medicine</i> , 1996, 334, 296-301. | 13.9 | 2,529 |
| 3 | Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension. <i>New England Journal of Medicine</i> , 2005, 353, 2148-2157. | 13.9 | 2,237 |
| 4 | ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension. <i>Journal of the American College of Cardiology</i> , 2009, 53, 1573-1619. | 1.2 | 1,797 |
| 5 | Inhaled Iloprost for Severe Pulmonary Hypertension. <i>New England Journal of Medicine</i> , 2002, 347, 322-329. | 13.9 | 1,626 |
| 6 | Clinical classification of pulmonary hypertension. <i>Journal of the American College of Cardiology</i> , 2004, 43, S5-S12. | 1.2 | 1,542 |
| 7 | Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study. <i>Lancet</i> , The, 2001, 358, 1119-1123. | 6.3 | 1,421 |
| 8 | Primary Pulmonary Hypertension. <i>New England Journal of Medicine</i> , 1997, 336, 111-117. | 13.9 | 1,294 |
| 9 | Continuous Subcutaneous Infusion of Treprostinil, a Prostacyclin Analogue, in Patients with Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2002, 165, 800-804. | 2.5 | 1,288 |
| 10 | Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension. <i>New England Journal of Medicine</i> , 2013, 369, 809-818. | 13.9 | 1,168 |
| 11 | Riociguat for the Treatment of Pulmonary Arterial Hypertension. <i>New England Journal of Medicine</i> , 2013, 369, 330-340. | 13.9 | 1,120 |
| 12 | ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension. <i>Circulation</i> , 2009, 119, 2250-2294. | 1.6 | 992 |
| 13 | Ambrisentan for the Treatment of Pulmonary Arterial Hypertension. <i>Circulation</i> , 2008, 117, 3010-3019. | 1.6 | 967 |
| 14 | Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. <i>New England Journal of Medicine</i> , 2015, 373, 834-844. | 13.9 | 906 |
| 15 | Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease. <i>Annals of Internal Medicine</i> , 2000, 132, 425. | 2.0 | 905 |
| 16 | Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. <i>European Heart Journal</i> , 2004, 25, 2243-2278. | 1.0 | 903 |
| 17 | Chronic Thromboembolic Pulmonary Hypertension. <i>Circulation</i> , 2006, 113, 2011-2020. | 1.6 | 791 |
| 18 | Selexipag for the Treatment of Pulmonary Arterial Hypertension. <i>New England Journal of Medicine</i> , 2015, 373, 2522-2533. | 13.9 | 790 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 19 | Chronic Thromboembolic Pulmonary Hypertension. <i>New England Journal of Medicine</i> , 2001, 345, 1465-1472. | 13.9 | 676 |
| 20 | Treatment of Primary Pulmonary Hypertension with Continuous Intravenous Prostacyclin (Epoprostenol). <i>Annals of Internal Medicine</i> , 1990, 112, 485. | 2.0 | 621 |
| 21 | Updated Treatment Algorithm of Pulmonary Arterial Hypertension. <i>Journal of the American College of Cardiology</i> , 2013, 62, D60-D72. | 1.2 | 596 |
| 22 | Randomized Study of Adding Inhaled Iloprost to Existing Bosentan in Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006, 174, 1257-1263. | 2.5 | 565 |
| 23 | Addition of Sildenafil to Long-Term Intravenous Epoprostenol Therapy in Patients with Pulmonary Arterial Hypertension. <i>Annals of Internal Medicine</i> , 2008, 149, 521. | 2.0 | 558 |
| 24 | Bosentan for Treatment of Inoperable Chronic Thromboembolic Pulmonary Hypertension. <i>Journal of the American College of Cardiology</i> , 2008, 52, 2127-2134. | 1.2 | 506 |
| 25 | Primary pulmonary hypertension. <i>Lancet, The</i> , 1998, 352, 719-725. | 6.3 | 505 |
| 26 | Complications of Right Heart Catheterization Procedures in Patients With Pulmonary Hypertension in Experienced Centers. <i>Journal of the American College of Cardiology</i> , 2006, 48, 2546-2552. | 1.2 | 498 |
| 27 | Addition of Inhaled Treprostinil to Oral Therapy for Pulmonary Arterial Hypertension. <i>Journal of the American College of Cardiology</i> , 2010, 55, 1915-1922. | 1.2 | 484 |
| 28 | Medical Therapy for Pulmonary Arterial Hypertension. <i>Chest</i> , 2007, 131, 1917-1928. | 0.4 | 477 |
| 29 | Updated Evidence-Based Treatment Algorithm in Pulmonary Arterial Hypertension. <i>Journal of the American College of Cardiology</i> , 2009, 54, S78-S84. | 1.2 | 463 |
| 30 | Ambrisentan Therapy for Pulmonary Arterial Hypertension. <i>Journal of the American College of Cardiology</i> , 2005, 46, 529-535. | 1.2 | 441 |
| 31 | Enhanced expression of transient receptor potential channels in idiopathic pulmonary arterial hypertension. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 13861-13866. | 3.3 | 395 |
| 32 | Dysfunctional Voltage-Gated K ⁺ Channels in Pulmonary Artery Smooth Muscle Cells of Patients With Primary Pulmonary Hypertension. <i>Circulation</i> , 1998, 98, 1400-1406. | 1.6 | 385 |
| 33 | Preoperative Partitioning of Pulmonary Vascular Resistance Correlates With Early Outcome After Thromboendarterectomy for Chronic Thromboembolic Pulmonary Hypertension. <i>Circulation</i> , 2004, 109, 18-22. | 1.6 | 377 |
| 34 | The right ventricle in pulmonary hypertension. <i>Coronary Artery Disease</i> , 2005, 16, 13-18. | 0.3 | 373 |
| 35 | Primary Pulmonary Hypertension. <i>Chest</i> , 1993, 104, 236-250. | 0.4 | 346 |
| 36 | An overview of the 6th World Symposium on Pulmonary Hypertension. <i>European Respiratory Journal</i> , 2019, 53, 1802148. | 3.1 | 345 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 37 | Upregulated <i>TRP</i> and enhanced capacitative Ca^{2+} entry in human pulmonary artery myocytes during proliferation. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2001, 280, H746-H755. | 1.5 | 316 |
| 38 | Efficacy and Safety of Oral Treprostinil Monotherapy for the Treatment of Pulmonary Arterial Hypertension. <i>Circulation</i> , 2013, 127, 624-633. | 1.6 | 291 |
| 39 | Effects of the Dual Endothelin Receptor Antagonist Bosentan in Patients With Pulmonary Arterial Hypertension. <i>Chest</i> , 2003, 124, 247-254. | 0.4 | 271 |
| 40 | Effects of Long-term Infusion of Prostacyclin (Epoprostenol) on Echocardiographic Measures of Right Ventricular Structure and Function in Primary Pulmonary Hypertension. <i>Circulation</i> , 1997, 95, 1479-1486. | 1.6 | 271 |
| 41 | Pulmonary Arterial Hypertension. <i>Journal of the American College of Cardiology</i> , 2008, 51, 1527-1538. | 1.2 | 269 |
| 42 | Oral Treprostinil for the Treatment of Pulmonary Arterial Hypertension in Patients Receiving Background Endothelin Receptor Antagonist and Phosphodiesterase Type 5 Inhibitor Therapy (The Tj ETQq0 0 0 rgt/Overload10 Tf 5 | 0.4 | 266 |
| 43 | Attenuated K^+ channel gene transcription in primary pulmonary hypertension. <i>Lancet</i> , The, 1998, 351, 726-727. | 6.3 | 263 |
| 44 | Cellular and molecular mechanisms of pulmonary vascular remodeling: role in the development of pulmonary hypertension. <i>Microvascular Research</i> , 2004, 68, 75-103. | 1.1 | 263 |
| 45 | Oral Hydralazine Therapy for Primary Pulmonary Hypertension. <i>New England Journal of Medicine</i> , 1980, 302, 69-73. | 13.9 | 256 |
| 46 | Introduction. <i>Chest</i> , 2004, 126, 7S-10S. | 0.4 | 244 |
| 47 | Bone morphogenetic proteins induce apoptosis in human pulmonary vascular smooth muscle cells. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2003, 285, L740-L754. | 1.3 | 237 |
| 48 | Long-term Treatment With Sildenafil Citrate in Pulmonary Arterial Hypertension. <i>Chest</i> , 2011, 140, 1274-1283. | 0.4 | 237 |
| 49 | Treprostinil, a Prostacyclin Analogue, in Pulmonary Arterial Hypertension Associated With Connective Tissue Disease. <i>Chest</i> , 2004, 126, 420-427. | 0.4 | 232 |
| 50 | Hemodynamic and Functional Assessment of Patients with Sickle Cell Disease and Pulmonary Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2007, 175, 1272-1279. | 2.5 | 227 |
| 51 | Long-Term Ambrisentan Therapy for the Treatment of Pulmonary Arterial Hypertension. <i>Journal of the American College of Cardiology</i> , 2009, 54, 1971-1981. | 1.2 | 227 |
| 52 | High prevalence of elevated clotting factor VIII in chronic thromboembolic pulmonary hypertension. <i>Thrombosis and Haemostasis</i> , 2003, 90, 372-376. | 1.8 | 221 |
| 53 | Efficacy and Safety of Treprostinil: An Epoprostenol Analog for Primary Pulmonary Hypertension. <i>Journal of Cardiovascular Pharmacology</i> , 2003, 41, 293-299. | 0.8 | 219 |
| 54 | Differential Effects of Stable Prostacyclin Analogs on Smooth Muscle Proliferation and Cyclic AMP Generation in Human Pulmonary Artery. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2002, 26, 194-201. | 1.4 | 211 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | CONTINUOUS INTRAVENOUS INFUSION OF EPOPROSTENOL FOR THE TREATMENT OF PORTOPULMONARY HYPERTENSION ¹ . <i>Transplantation</i> , 1997, 63, 604-606. | 0.5 | 208 |
| 56 | Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension. <i>Journal of the American College of Cardiology</i> , 2004, 43, S81-S88. | 1.2 | 206 |
| 57 | Pathogenesis of Pulmonary Arterial Hypertension. <i>Circulation</i> , 2005, 111, 534-538. | 1.6 | 186 |
| 58 | The Acute Administration of Vasodilators in Primary Pulmonary Hypertension: Experience from the National Institutes of Health Registry on Primary Pulmonary Hypertension. <i>The American Review of Respiratory Disease</i> , 1989, 140, 1623-1630. | 2.9 | 177 |
| 59 | Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2). <i>European Respiratory Journal</i> , 2015, 45, 1303-1313. | 3.1 | 174 |
| 60 | Is Methamphetamine Use Associated With Idiopathic Pulmonary Arterial Hypertension?. <i>Chest</i> , 2006, 130, 1657-1663. | 0.4 | 173 |
| 61 | A Functional Single-Nucleotide Polymorphism in the <i>TRPC6</i> Gene Promoter Associated With Idiopathic Pulmonary Arterial Hypertension. <i>Circulation</i> , 2009, 119, 2313-2322. | 1.6 | 173 |
| 62 | Ambrisentan Therapy in Patients With Pulmonary Arterial Hypertension Who Discontinued Bosentan or Sitaxsentan Due to Liver Function Test Abnormalities. <i>Chest</i> , 2009, 135, 122-129. | 0.4 | 167 |
| 63 | Chronic hypoxia decreases K_{V} channel expression and function in pulmonary artery myocytes. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2001, 280, L801-L812. | 1.3 | 159 |
| 64 | Endothelin receptor antagonists in pulmonary arterial hypertension. <i>Journal of the American College of Cardiology</i> , 2004, 43, S62-S67. | 1.2 | 153 |
| 65 | Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. <i>Journal of Rheumatology</i> , 2007, 34, 2417-22. | 1.0 | 152 |
| 66 | Distinctive Clinical Features of Portopulmonary Hypertension. <i>Chest</i> , 1997, 112, 980-986. | 0.4 | 149 |
| 67 | Chronic thromboembolic pulmonary hypertension. <i>Lancet Respiratory Medicine</i> , 2014, 2, 573-582. | 5.2 | 146 |
| 68 | Sustained membrane depolarization and pulmonary artery smooth muscle cell proliferation. <i>American Journal of Physiology - Cell Physiology</i> , 2000, 279, C1540-C1549. | 2.1 | 145 |
| 69 | Clinical trial design and new therapies for pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2019, 53, 1801908. | 3.1 | 142 |
| 70 | Function of Kv1.5 channels and genetic variations of <i>KCNA5</i> in patients with idiopathic pulmonary arterial hypertension. <i>American Journal of Physiology - Cell Physiology</i> , 2007, 292, C1837-C1853. | 2.1 | 141 |
| 71 | Borderline Pulmonary Arterial Pressure Is Associated with Decreased Exercise Capacity in Scleroderma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009, 180, 881-886. | 2.5 | 141 |
| 72 | Macitentan in pulmonary hypertension due to left ventricular dysfunction. <i>European Respiratory Journal</i> , 2018, 51, 1701886. | 3.1 | 139 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Favorable Effects of Inhaled Treprostinil in Severe Pulmonary Hypertension. Journal of the American College of Cardiology, 2006, 48, 1672-1681. | 1.2 | 135 |
| 74 | Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial. Annals of the Rheumatic Diseases, 2017, 76, 1219-1227. | 0.5 | 135 |
| 75 | Capacitative Ca ²⁺ entry in agonist-induced pulmonary vasoconstriction. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2001, 280, L870-L880. | 1.3 | 134 |
| 76 | New Treatments for Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2002, 165, 1209-1216. | 2.5 | 129 |
| 77 | Contemporary Trends in the Diagnosis and Management of Pulmonary Arterial Hypertension. Chest, 2013, 143, 324-332. | 0.4 | 122 |
| 78 | PORTOPULMONARY HYPERTENSION AND THE LIVER TRANSPLANT CANDIDATE. Transplantation, 1999, 67, 1087-1093. | 0.5 | 122 |
| 79 | Evaluation and Management of the Patient with Pulmonary Arterial Hypertension. Annals of Internal Medicine, 2005, 143, 282. | 2.0 | 121 |
| 80 | Safety and Efficacy of Inhaled Treprostinil as Add-On Therapy to Bosentan in Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2006, 48, 1433-1437. | 1.2 | 115 |
| 81 | SUCCESSFUL USE OF CHRONIC EPOPROSTENOL AS A BRIDGE TO LIVER TRANSPLANTATION IN SEVERE PORTOPULMONARY HYPERTENSION ¹ . Transplantation, 1998, 65, 457-459. | 0.5 | 115 |
| 82 | New Trial Designs and Potential Therapies for Pulmonary Artery Hypertension. Journal of the American College of Cardiology, 2013, 62, D82-D91. | 1.2 | 113 |
| 83 | Epoprostenol for Treatment of Pulmonary Hypertension in Patients With Systemic Lupus Erythematosus. Chest, 2000, 117, 14-18. | 0.4 | 109 |
| 84 | Hemodynamics at rest and during exercise after oral hydralazine in patients with cor pulmonale. American Journal of Cardiology, 1981, 47, 116-122. | 0.7 | 105 |
| 85 | Molecular basis and function of voltage-gated K ⁺ channels in pulmonary arterial smooth muscle cells. American Journal of Physiology - Lung Cellular and Molecular Physiology, 1998, 274, L621-L635. | 1.3 | 103 |
| 86 | CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION. Clinics in Chest Medicine, 2001, 22, 561-581. | 0.8 | 102 |
| 87 | Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: The TReprostinil sodium Inhalation Used in the Management of Pulmonary arterial Hypertension (TRIUMPH) study open-label extension. Journal of Heart and Lung Transplantation, 2011, 30, 1327-1333. | 0.3 | 98 |
| 88 | Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension. European Respiratory Journal, 2017, 50, 1602493. | 3.1 | 97 |
| 89 | Prostacyclin and PGE1 Treatment of Pulmonary Hypertension. The American Review of Respiratory Disease, 1987, 136, 773-776. | 2.9 | 96 |
| 90 | Treatment of Primary Pulmonary Hypertension with Nifedipine. Annals of Internal Medicine, 1983, 99, 433. | 2.0 | 92 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | Primary Pulmonary Hypertension. <i>Medicine (United States)</i> , 1986, 65, 56. | 0.4 | 91 |
| 92 | Bosentan Inhibits Transient Receptor Potential Channel Expression in Pulmonary Vascular Myocytes. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2004, 170, 1101-1107. | 2.5 | 91 |
| 93 | Pathology and pathophysiology of primary pulmonary hypertension. <i>American Journal of Cardiology</i> , 1995, 75, 51A-54A. | 0.7 | 85 |
| 94 | ARIES-3: Ambrisentan Therapy in a Diverse Population of Patients with Pulmonary Hypertension. <i>Cardiovascular Therapeutics</i> , 2012, 30, 93-99. | 1.1 | 85 |
| 95 | Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality. <i>Journal of the American College of Cardiology</i> , 2018, 71, 752-763. | 1.2 | 82 |
| 96 | Independence of Oxygen Consumption and Systemic Oxygen Transport in Patients with Either Stable Pulmonary Hypertension or Refractory Left Ventricular Failure ^{1&#x2013;4} . <i>The American Review of Respiratory Disease</i> , 1983, 128, 30-33. | 2.9 | 80 |
| 97 | Pulmonary Arterial Hypertension. <i>Proceedings of the American Thoracic Society</i> , 2006, 3, 111-115. | 3.5 | 80 |
| 98 | Augmented K ⁺ currents and mitochondrial membrane depolarization in pulmonary artery myocyte apoptosis. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2001, 281, L887-L894. | 1.3 | 79 |
| 99 | Upregulation of Na ⁺ /Ca ²⁺ exchanger contributes to the enhanced Ca ²⁺ entry in pulmonary artery smooth muscle cells from patients with idiopathic pulmonary arterial hypertension. <i>American Journal of Physiology - Cell Physiology</i> , 2007, 292, C2297-C2305. | 2.1 | 79 |
| 100 | Temporal trends and drug exposures in pulmonary hypertension: An American experience. <i>American Heart Journal</i> , 2006, 152, 521-526. | 1.2 | 78 |
| 101 | Identification of putative endothelial progenitor cells (CD34 ⁺ CD133 ⁺ Flk-1 ⁻) in endarterectomized tissue of patients with chronic thromboembolic pulmonary hypertension. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2009, 296, L870-L878. | 1.3 | 77 |
| 102 | Longterm Survival Among Patients with Scleroderma-associated Pulmonary Arterial Hypertension Treated with Intravenous Epoprostenol. <i>Journal of Rheumatology</i> , 2009, 36, 2244-2249. | 1.0 | 77 |
| 103 | Clinical trials with endothelin receptor antagonists: What went wrong and where can we improve?. <i>Life Sciences</i> , 2012, 91, 528-539. | 2.0 | 76 |
| 104 | Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study. <i>American Journal of Cardiovascular Drugs</i> , 2018, 18, 37-47. | 1.0 | 69 |
| 105 | Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension. <i>Circulation</i> , 2019, 139, 2440-2450. | 1.6 | 67 |
| 106 | Bosentan: a dual endothelin receptor antagonist. <i>Expert Opinion on Investigational Drugs</i> , 2002, 11, 991-1002. | 1.9 | 65 |
| 107 | SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension. <i>European Heart Journal</i> , 2017, 38, 1147-1155. | 1.0 | 65 |
| 108 | Acute effects of the combination of sildenafil and inhaled treprostinil on haemodynamics and gas exchange in pulmonary hypertension. <i>Pulmonary Pharmacology and Therapeutics</i> , 2008, 21, 824-832. | 1.1 | 64 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 109 | The pulmonary arterial hypertension quality enhancement research initiative: comparison of patients with idiopathic PAH to patients with systemic sclerosis-associated PAH. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 249-252. | 0.5 | 63 |
| 110 | High sodium bicarbonate and acetate hemodialysis: Double-blind crossover comparison of hemodynamic and ventilatory effects. <i>Kidney International</i> , 1983, 24, 240-245. | 2.6 | 62 |
| 111 | Future Perspectives for the Treatment of Pulmonary Arterial Hypertension. <i>Journal of the American College of Cardiology</i> , 2009, 54, S108-S117. | 1.2 | 62 |
| 112 | Patients with pulmonary arterial hypertension with and without cardiovascular risk factors: Results from the AMBITION trial. <i>Journal of Heart and Lung Transplantation</i> , 2019, 38, 1286-1295. | 0.3 | 62 |
| 113 | The physiological basis of pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2022, 59, 2102334. | 3.1 | 61 |
| 114 | Executive Summary. <i>Chest</i> , 2004, 126, 4S-6S. | 0.4 | 60 |
| 115 | Efficacy, safety and clinical pharmacology of macitentan in comparison to other endothelin receptor antagonists in the treatment of pulmonary arterial hypertension. <i>Expert Opinion on Drug Safety</i> , 2014, 13, 391-405. | 1.0 | 60 |
| 116 | Metabolic dysfunction in pulmonary hypertension: from basic science to clinical practice. <i>European Respiratory Review</i> , 2017, 26, 170094. | 3.0 | 60 |
| 117 | Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study. <i>Lancet Respiratory Medicine</i> , 2016, 4, 894-901. | 5.2 | 59 |
| 118 | Therapy of Pulmonary Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2002, 166, 1308-1309. | 2.5 | 57 |
| 119 | Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: A Delphi consensus study with cluster analysis. <i>Arthritis and Rheumatism</i> , 2008, 59, 867-875. | 6.7 | 56 |
| 120 | Endothelin receptor antagonists for the treatment of pulmonary artery hypertension. <i>Life Sciences</i> , 2012, 91, 517-521. | 2.0 | 56 |
| 121 | Influence of Prostaglandin Synthesis Inhibitors on Pulmonary Vasodilatory Effects of Hydralazine in Dogs with Hypoxic Pulmonary Vasoconstriction. <i>Journal of Clinical Investigation</i> , 1981, 67, 193-200. | 3.9 | 55 |
| 122 | A comparison of the acute hemodynamic effects of prostacyclin and hydralazine in primary pulmonary hypertension. <i>American Heart Journal</i> , 1985, 110, 1200-1204. | 1.2 | 52 |
| 123 | Effect of Macitentan on Hospitalizations. <i>JACC: Heart Failure</i> , 2015, 3, 1-8. | 1.9 | 51 |
| 124 | Mortality From Primary Pulmonary Hypertension in the United States, 1979-1996. <i>Chest</i> , 2000, 117, 796-800. | 0.4 | 50 |
| 125 | Hemodynamics and Epoprostenol Use Are Associated With Thrombocytopenia in Pulmonary Arterial Hypertension. <i>Chest</i> , 2009, 135, 130-136. | 0.4 | 49 |
| 126 | Current and Future Management of Chronic Thromboembolic Pulmonary Hypertension: From Diagnosis to Treatment Responses. <i>Proceedings of the American Thoracic Society</i> , 2006, 3, 601-607. | 3.5 | 48 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 127 | Primary Pulmonary Hypertension: An Unusual Case Associated with Extrahepatic Portal Hypertension. <i>Hepatology</i> , 1983, 3, 588-592. | 3.6 | 48 |
| 128 | Treprostinil Administered to Treat Pulmonary Arterial Hypertension Using a Fully Implantable Programmable Intravascular Delivery System. <i>Chest</i> , 2016, 150, 27-34. | 0.4 | 48 |
| 129 | Long-term results from the EARLY study of bosentan in WHO functional class II pulmonary arterial hypertension patients. <i>International Journal of Cardiology</i> , 2014, 172, 332-339. | 0.8 | 47 |
| 130 | Intravascular Ultrasound Pulmonary Artery Denervation to Treat Pulmonary Arterial Hypertension (TROPHY1). <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 989-999. | 1.1 | 47 |
| 131 | Macitentan Improves Health-Related Quality of Life for Patients With Pulmonary Arterial Hypertension. <i>Chest</i> , 2017, 151, 106-118. | 0.4 | 46 |
| 132 | c-Jun Decreases Voltage-Gated K ⁺ Channel Activity in Pulmonary Artery Smooth Muscle Cells. <i>Circulation</i> , 2001, 104, 1557-1563. | 1.6 | 43 |
| 133 | Successful Withdrawal of Long-term Epoprostenol Therapy for Pulmonary Arterial Hypertension. <i>Chest</i> , 2003, 124, 1612-1615. | 0.4 | 43 |
| 134 | Metered dose inhaler delivery of treprostinil for the treatment of pulmonary hypertension. <i>Pulmonary Pharmacology and Therapeutics</i> , 2009, 22, 50-56. | 1.1 | 43 |
| 135 | Inhaled treprostinil: a therapeutic review. <i>Drug Design, Development and Therapy</i> , 2012, 6, 19. | 2.0 | 43 |
| 136 | Endothelin in Health and Disease: Endothelin Receptor Antagonists in the Management of Pulmonary Artery Hypertension. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2002, 7, 9-19. | 1.0 | 41 |
| 137 | Update in Pulmonary Hypertension 2005. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006, 173, 499-505. | 2.5 | 40 |
| 138 | Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study. <i>European Journal of Heart Failure</i> , 2019, 21, 352-359. | 2.9 | 40 |
| 139 | Investigation and Management of Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease. <i>The American Review of Respiratory Disease</i> , 1993, 148, 1414-1417. | 2.9 | 39 |
| 140 | Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN. <i>European Respiratory Journal</i> , 2015, 46, 1711-1720. | 3.1 | 39 |
| 141 | Risk assessment in pulmonary arterial hypertension: Insights from the GRIPHON study. <i>Journal of Heart and Lung Transplantation</i> , 2020, 39, 300-309. | 0.3 | 39 |
| 142 | Gas exchange during dialysis. <i>American Journal of Medicine</i> , 1984, 77, 255-260. | 0.6 | 38 |
| 143 | Recreational Use of Aminorex and Pulmonary Hypertension. <i>Chest</i> , 2000, 118, 1496-1497. | 0.4 | 38 |
| 144 | Action of fenfluramine on voltage-gated K ⁺ channels in human pulmonary-artery smooth-muscle cells. <i>Lancet</i> , 1998, 352, 290. | 6.3 | 37 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 145 | Echocardiography as an Outcome Measure in Scleroderma-related Pulmonary Arterial Hypertension: A Systematic Literature Analysis by the EPOSS Group. <i>Journal of Rheumatology</i> , 2010, 37, 105-115. | 1.0 | 37 |
| 146 | Long-term Effects of Nitrendipine on Hemodynamics and Oxygen Transport in Patients with Cor Pulmonale. <i>Chest</i> , 1986, 89, 141-145. | 0.4 | 36 |
| 147 | Pulmonary arterial hypertension: a look to the future. <i>Journal of the American College of Cardiology</i> , 2004, 43, S89-S90. | 1.2 | 34 |
| 148 | Validation of the 6 min walk test according to the OMERACT filter: a systematic literature review by the EPOSS-OMERACT group. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1360-1363. | 0.5 | 34 |
| 149 | Safety and Efficacy of Transition from Systemic Prostanoids to Inhaled Treprostinil in Pulmonary Arterial Hypertension. <i>American Journal of Cardiology</i> , 2012, 110, 1546-1550. | 0.7 | 34 |
| 150 | Association between six-minute walk distance and long-term outcomes in patients with pulmonary arterial hypertension: Data from the randomized SERAPHIN trial. <i>PLoS ONE</i> , 2018, 13, e0193226. | 1.1 | 33 |
| 151 | Complete results of the first randomized, placebo-controlled study of bosentan, a dual endothelin receptor antagonist, in pulmonary arterial hypertension. <i>Current Therapeutic Research</i> , 2002, 63, 227-246. | 0.5 | 32 |
| 152 | Epoprostenol Therapy as a Bridge to Pulmonary Thromboendarterectomy for Chronic Thromboembolic Pulmonary Hypertension. <i>Chest</i> , 2003, 123, 319-320. | 0.4 | 32 |
| 153 | Pulmonary vasoconstrictor effects of prostacyclin in rats: potential role of thromboxane receptors. <i>Journal of Applied Physiology</i> , 1996, 81, 2595-2603. | 1.2 | 31 |
| 154 | Short-term Outcome and Predictors of Adverse Events following Pulmonary Thromboendarterectomy. <i>World Journal of Surgery</i> , 1998, 22, 1029-1033. | 0.8 | 30 |
| 155 | Effects of oral hydralazine on gas exchange in patients with cor pulmonale. <i>American Journal of Medicine</i> , 1983, 75, 937-942. | 0.6 | 29 |
| 156 | Rapid Transition from Inhaled Iloprost to Inhaled Treprostinil in Patients with Pulmonary Arterial Hypertension. <i>Cardiovascular Therapeutics</i> , 2013, 31, 38-44. | 1.1 | 29 |
| 157 | Prednisolone inhibits PDGF-induced nuclear translocation of NF- κ B in human pulmonary artery smooth muscle cells. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2008, 295, L648-L657. | 1.3 | 28 |
| 158 | ARIES-1: A PLACEBO-CONTROLLED, EFFICACY AND SAFETY STUDY OF AMBRISENTAN IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION. <i>Chest</i> , 2006, 130, 121S. | 0.4 | 27 |
| 159 | Two formulations of epoprostenol sodium in the treatment of pulmonary arterial hypertension: EPITOME-1 (epoprostenol for injection in pulmonary arterial hypertension), a phase IV, open-label, randomized study. <i>American Heart Journal</i> , 2014, 167, 218-225.e1. | 1.2 | 27 |
| 160 | Increased Levels of Prostaglandin D2 Suggest Macrophage Activation in Patients With Primary Pulmonary Hypertension. <i>Chest</i> , 2001, 120, 1639-1644. | 0.4 | 26 |
| 161 | Worldwide Physician Education and Training in Pulmonary Hypertension. <i>Chest</i> , 2010, 137, 85S-94S. | 0.4 | 26 |
| 162 | Relation between mixed venous oxygen tension and pulmonary vascular tone during normoxic, hyperoxic and hypoxic ventilation in dogs. <i>American Journal of Cardiology</i> , 1984, 54, 1118-1123. | 0.7 | 25 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 163 | The 6-Minute Walk Test in Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 186, 396-397. | 2.5 | 25 |
| 164 | Treprostinil for the treatment of pulmonary arterial hypertension. <i>Expert Review of Cardiovascular Therapy</i> , 2013, 11, 13-25. | 0.6 | 25 |
| 165 | Continuous Intravenous Epoprostenol Therapy for Pulmonary Hypertension in Gaucher's Disease. <i>Chest</i> , 1999, 116, 1127-1129. | 0.4 | 23 |
| 166 | Long-term sildenafil added to intravenous epoprostenol in patients with pulmonary arterial hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2014, 33, 689-697. | 0.3 | 23 |
| 167 | NEW AND EXPERIMENTAL THERAPIES FOR PULMONARY HYPERTENSION. <i>Clinics in Chest Medicine</i> , 2001, 22, 539-545. | 0.8 | 22 |
| 168 | Comparison of hemodynamic parameters in treatment-naïve and pre-treated patients with pulmonary arterial hypertension in the randomized phase III PATENT-1 study. <i>Journal of Heart and Lung Transplantation</i> , 2017, 36, 509-519. | 0.3 | 22 |
| 169 | The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the <sc>GRIPHON</sc> study. <i>European Journal of Heart Failure</i> , 2022, 24, 205-214. | 2.9 | 22 |
| 170 | Endothelin-1 and the Pulmonary Vascular Response to Altitude. <i>Circulation</i> , 2006, 114, 1350-1351. | 1.6 | 21 |
| 171 | Riociguat for Pulmonary Hypertension. <i>New England Journal of Medicine</i> , 2013, 369, 2266-2268. | 13.9 | 21 |
| 172 | Relationship Between Time From Diagnosis and Morbidity/Mortality in Pulmonary Arterial Hypertension. <i>Chest</i> , 2021, 160, 277-286. | 0.4 | 21 |
| 173 | The Influence of the Transmembrane Sodium Gradient on the Responses of Pulmonary Arteries to Decreases in Oxygen Tension. <i>The American Review of Respiratory Disease</i> , 1989, 139, 933-939. | 2.9 | 20 |
| 174 | Exercise-Induced Pulmonary Arterial Hypertension. <i>Circulation</i> , 2008, 118, 2120-2121. | 1.6 | 20 |
| 175 | Cardiovascular Effects of Vasodilator Therapy for Pulmonary Arterial Hypertension. <i>Clinics in Chest Medicine</i> , 1983, 4, 309-319. | 0.8 | 20 |
| 176 | Safety and efficacy evaluation of ambrisentan in pulmonary hypertension. <i>Expert Opinion on Drug Safety</i> , 2012, 11, 1003-1011. | 1.0 | 19 |
| 177 | Initial combination therapy with ambrisentan + tadalafil on pulmonary arterial hypertension-related hospitalization in the AMBITION trial. <i>Journal of Heart and Lung Transplantation</i> , 2019, 38, 194-202. | 0.3 | 19 |
| 178 | Medical and Surgical Treatment Options for Pulmonary Hypertension. <i>American Journal of the Medical Sciences</i> , 1998, 315, 179-184. | 0.4 | 19 |
| 179 | Reversible pulmonary hypertension associated with anorexigen use. <i>American Journal of Medicine</i> , 1991, 91, 97-99. | 0.6 | 18 |
| 180 | lloprost inhalation solution for the treatment of pulmonary arterial hypertension. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 1921-1930. | 0.9 | 18 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 181 | Roles of K ⁺ and Cl ⁻ Channels in Camp-Induced Pulmonary Vasodilation. <i>Experimental Lung Research</i> , 1998, 24, 71-83. | 0.5 | 17 |
| 182 | Ambrisentan for pulmonary arterial hypertension. <i>Future Cardiology</i> , 2005, 1, 425-432. | 0.5 | 17 |
| 183 | Calcium Channel Blockers in Primary Pulmonary Hypertension. <i>Chest</i> , 1985, 88, 257S-260S. | 0.4 | 16 |
| 184 | Cellular and molecular mechanisms responsible for the pathogenesis of primary pulmonary hypertension. <i>Pediatric Pulmonology</i> , 1999, 27, 194-197. | 1.0 | 16 |
| 185 | The study of risk in pulmonary arterial hypertension. <i>European Respiratory Review</i> , 2012, 21, 234-238. | 3.0 | 15 |
| 186 | Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI ₂) Receptor Agonist in Pulmonary Arterial Hypertension (GRIPHON) study. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, 401-408. | 0.3 | 15 |
| 187 | Risk-stratified outcomes with initial combination therapy in pulmonary arterial hypertension: Application of the REVEAL risk score. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, 1410-1417. | 0.3 | 15 |
| 188 | Noninvasive Evaluation of Right Ventricular Function. <i>Clinics in Chest Medicine</i> , 1987, 8, 65-80. | 0.8 | 15 |
| 189 | Approach to the Diagnosis and Treatment of Pulmonary Hypertension. <i>Chest</i> , 1989, 96, 659-664. | 0.4 | 14 |
| 190 | Indomethacin Prevents Ventilation-Induced Decreases in Pulmonary Vascular Resistance of the Middle Region in Fetal Lambs. <i>Pediatric Research</i> , 1991, 29, 449-454. | 1.1 | 14 |
| 191 | Chronic thromboembolic pulmonary hypertension. <i>Progress in Cardiovascular Diseases</i> , 2002, 45, 203-212. | 1.6 | 14 |
| 192 | Combination therapy for pulmonary hypertension: A glimpse into the future?. <i>Critical Care Medicine</i> , 2000, 28, 896-897. | 0.4 | 13 |
| 193 | Pulmonary Vascular Structural and Functional Changes in Papain-induced Emphysema in Dogs. <i>The American Review of Respiratory Disease</i> , 1987, 136, 704-709. | 2.9 | 12 |
| 194 | Performance of new criteria for right ventricular hypertrophy and myocardial infarction in patients with pulmonary hypertension due to cor pulmonale and mitral stenosis. <i>Journal of Electrocardiology</i> , 1991, 24, 231-237. | 0.4 | 12 |
| 195 | Cor Pulmonale Revisited. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1112-1113. | 1.2 | 12 |
| 196 | The Beta-Adrenergic Receptor in Pulmonary Arterial Hypertension. <i>Journal of the American College of Cardiology</i> , 2015, 65, 681-683. | 1.2 | 12 |
| 197 | Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension. <i>Advances in Therapy</i> , 2022, 39, 796-810. | 1.3 | 12 |
| 198 | Primary pulmonary hypertension: new approaches to therapy. <i>American Heart Journal</i> , 1980, 100, 757-759. | 1.2 | 10 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 199 | Central Venous Blood Oxygen Saturation Monitoring in Patients With Chronic Pulmonary Arterial Hypertension Treated With Continuous IV Epoprostenol. <i>Chest</i> , 2007, 132, 786-792. | 0.4 | 10 |
| 200 | Exercise training for pulmonary hypertension: another prescription to write?. <i>European Respiratory Journal</i> , 2012, 40, 7-8. | 3.1 | 10 |
| 201 | Use of clinically relevant responder threshold criteria to evaluate the response to treatment in the Phase III PATENT-1 study. <i>Journal of Heart and Lung Transplantation</i> , 2015, 34, 338-347. | 0.3 | 10 |
| 202 | Inhibition of K ⁺ Channel Activity in Human Pulmonary Artery Smooth Muscle Cells by Serum from Patients with Pulmonary Hypertension Secondary to Congenital Heart Disease. <i>Pediatric Research</i> , 2001, 50, 23-28. | 1.1 | 9 |
| 203 | Metabolic Dysfunction in the Pathogenesis of Pulmonary Hypertension. <i>Cell Metabolism</i> , 2010, 12, 313-314. | 7.2 | 9 |
| 204 | Effects of Interleukin-2 on Oxygen Delivery and Consumption in Patients with Advanced Malignancy. <i>Chest</i> , 1988, 94, 816-821. | 0.4 | 8 |
| 205 | Primary Pulmonary Hypertension. <i>Drugs</i> , 1992, 43, 37-43. | 4.9 | 8 |
| 206 | Systemic sclerosis-associated pulmonary hypertension: why disease-specific composite endpoints are needed. <i>Arthritis Research and Therapy</i> , 2011, 13, 114. | 1.6 | 8 |
| 207 | Cor Pulmonale Revisited. From Ferrer and Harvey to the Present. <i>Annals of the American Thoracic Society</i> , 2018, 15, S42-S44. | 1.5 | 8 |
| 208 | Integrating Data From Randomized Controlled Trials and Observational Studies to Assess Survival in Rare Diseases. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e005095. | 0.9 | 8 |
| 209 | Therapy of pulmonary hypertension: Targeting pathogenic mechanisms with selective treatment delivery. <i>Critical Care Medicine</i> , 2001, 29, 1086-1087. | 0.4 | 8 |
| 210 | Medical and Surgical Treatment Options for Pulmonary Hypertension. <i>American Journal of the Medical Sciences</i> , 1998, 315, 179-184. | 0.4 | 7 |
| 211 | Treatment of Pulmonary Arterial Hypertension Due to Scleroderma: Challenges for the Future. <i>Rheumatic Disease Clinics of North America</i> , 2008, 34, 191-197. | 0.8 | 7 |
| 212 | <i>BMPR2</i> Mutation and Outcome in Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008, 177, 1300-1301. | 2.5 | 7 |
| 213 | Medical Treatment of Pulmonary Arterial Hypertension. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2009, 30, 484-492. | 0.8 | 6 |
| 214 | Treatment of Pulmonary Hypertension Caused by Left Heart Failure With Pulmonary Arterial Hypertension-â€“Specific Therapies. <i>Circulation</i> , 2013, 128, 475-476. | 1.6 | 6 |
| 215 | Pulmonary Artery Denervation for Pulmonary Artery Hypertension. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 2024-2025. | 1.1 | 5 |
| 216 | Improving patient outcomes in pulmonary hypertension. <i>European Respiratory Review</i> , 2015, 24, 550-551. | 3.0 | 5 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 217 | Pulmonary Hypertension Overlap Syndromes. <i>Journal of the American College of Cardiology</i> , 2016, 68, 379-381. | 1.2 | 5 |
| 218 | Assessing Prognosis of Pulmonary Arterial Hypertension in the Therapeutic Era. <i>Circulation</i> , 2018, 137, 705-706. | 1.6 | 5 |
| 219 | Analysis of the Validation Status of Quality of Life and Functional Disability Measures in Pulmonary Arterial Hypertension Related to Systemic Sclerosis: Results of a Systematic Literature Analysis by the Expert Panel on Outcomes Measures in Pulmonary Arterial Hypertension Related to Systemic Sclerosis (EPOSS). <i>Journal of Rheumatology</i> , 2011, 38, 2419-2427. | 1.0 | 4 |
| 220 | Navigating the uncharted waters of combination therapy in pulmonary arterial hypertension: COMPASS or dead-reckoning. <i>European Respiratory Journal</i> , 2015, 46, 297-298. | 3.1 | 4 |
| 221 | Comparative bioavailability of inhaled treprostinil administered as LIQ861 and Tyvaso® in healthy subjects. <i>Vascular Pharmacology</i> , 2021, 138, 106840. | 1.0 | 4 |
| 222 | Effects of Nitrendipine and Hypoxia on Pulmonary Vascular Resistance in Experimental Emphysema. <i>The American Review of Respiratory Disease</i> , 1990, 142, 625-630. | 2.9 | 3 |
| 223 | Cardiovascular effects of pulmonary hypertension. <i>Trends in Cardiovascular Medicine</i> , 1991, 1, 65-69. | 2.3 | 3 |
| 224 | The Renin-Angiotensin System and the "Lesser Circulation". <i>Chest</i> , 1996, 110, 584-585. | 0.4 | 3 |
| 225 | Clinical trials and basic research: defining mechanisms and improving treatment in connective tissue disease. <i>Arthritis Research and Therapy</i> , 2007, 9, S10. | 1.6 | 3 |
| 226 | Combination Therapy for Pulmonary Artery Hypertension: What Is the Evidence?. <i>Cardiology</i> , 2011, 120, 172-173. | 0.6 | 3 |
| 227 | A paradigm shift in pulmonary arterial hypertension management. <i>European Respiratory Review</i> , 2013, 22, 423-426. | 3.0 | 3 |
| 228 | New horizons in pulmonary arterial hypertension management. <i>European Respiratory Review</i> , 2014, 23, 408-409. | 3.0 | 3 |
| 229 | Are Animal Models in Pulmonary Hypertension Relevant to the Clinical Disease? —. <i>Journal of the American College of Cardiology</i> , 2016, 67, 2047-2049. | 1.2 | 3 |
| 230 | Therapy of Pulmonary Heart Disease. , 1984, , 325-353. | | 3 |
| 231 | Nafazatrom (Bay G 6575) blunts canine hypoxic pulmonary vasoconstriction: Evidence for a prostaglandin-mediated mechanism. <i>Prostaglandins, Leukotrienes, and Medicine</i> , 1985, 18, 95-104. | 0.8 | 2 |
| 232 | Oxygen Therapy Titrated to Raise Mixed Venous Oxygen Content in COPD. <i>Chest</i> , 1986, 89, 343-347. | 0.4 | 2 |
| 233 | Management following pulmonary thromboendarterectomy: Experience versus evidence*. <i>Critical Care Medicine</i> , 2005, 33, 2132-2133. | 0.4 | 2 |
| 234 | Endothelin and the Systemic Circulation. <i>Journal of the American College of Cardiology</i> , 2009, 53, 1318-1319. | 1.2 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 235 | Approach to pulmonary hypertension. Current Rheumatology Reports, 2000, 2, 517-523. | 2.1 | 1 |
| 236 | Bosentan. American Journal of Cardiovascular Drugs, 2002, 2, 343. | 1.0 | 1 |
| 237 | Editor's response to "Ethical issues associated with globalization of placebo-controlled trials in pulmonary arterial hypertension". Journal of Heart and Lung Transplantation, 2010, 29, 827-828. | 0.3 | 1 |
| 238 | Future Perspectives in Pulmonary Arterial Hypertension. Progress in Respiratory Research, 2012, , 276-279. | 0.1 | 1 |
| 239 | Overdue to understand anticoagulation in pulmonary arterial hypertension. Pulmonary Circulation, 2018, 8, 1-1. | 0.8 | 1 |
| 240 | Cellular and molecular mechanisms responsible for the pathogenesis of primary pulmonary hypertension. , 1999, 27, 194. | | 1 |
| 241 | Altered Expression and Function of Kv Channels in Primary Pulmonary Hypertension. , 2001, , 821-836. | | 1 |
| 242 | Pulmonary Hypertension: Current Management and Future Directions. Handbook of Experimental Pharmacology, 2013, 218, 551-555. | 0.9 | 1 |
| 243 | Pulmonary Hypertension: Current Management and Future Directions. Handbook of Experimental Pharmacology, 2013, , 551-555. | 0.9 | 1 |
| 244 | Thyrotoxicosis as a Risk Factor for Pulmonary Arterial Hypertension. Annals of Internal Medicine, 2006, 144, 222. | 2.0 | 1 |
| 245 | The Sodium Gradient, Potassium Channels, and Regulation of Calcium in Pulmonary and Mesenteric Arterial Smooth Muscles: Effects of Hypoxia. , 1993, , 205-222. | | 1 |
| 246 | It's Time to Put the Term "Pulmonary Vasodilators" to Rest. JACC Basic To Translational Science, 2021, 6, 870-871. | 1.9 | 1 |
| 247 | Effects of chronic anemic hypoxia on skeletal muscle mass, protein degradation, and oxygen utilization. Journal of Critical Care, 1990, 5, 10-19. | 1.0 | 0 |
| 248 | Different Vasoactive Mechanisms of Various Pulmonary Vasodilators-To the Editor. Chest, 1994, 105, 1920-1921. | 0.4 | 0 |
| 249 | IV Epoprostenol in Gaucher's Disease. Chest, 2000, 117, 1821. | 0.4 | 0 |
| 250 | Bosentan: profile report. Drugs and Therapy Perspectives, 2003, 19, 5-6. | 0.3 | 0 |
| 251 | Pulmonary Arterial Hypertension. , 2008, , 759-771. | | 0 |
| 252 | Pulmonary Vasodilators in COPD. , 2009, , 699-704. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|----|-----------|
| 253 | Pulmonary Vasodilators. , 2002, , 605-609. | | 0 |
| 254 | Clinical Evaluation. , 1984, , 107-115. | | 0 |